We are live on ! Find out more
JAZZ icon

Jazz Pharmaceuticals

357 hedge funds and large institutions have $8.94B invested in Jazz Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 76 funds opening new positions, 126 increasing their positions, 120 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

111% more first-time investments, than exits

New positions opened: 76 | Existing positions closed: 36

25% more funds holding in top 10

Funds holding in top 10: 1215 (+3)

10% more funds holding

Funds holding: 325357 (+32)

5% more repeat investments, than reductions

Existing positions increased: 126 | Existing positions reduced: 120

4% more capital invested

Capital invested by funds: $8.58B → $8.94B (+$355M)

27% less call options, than puts

Call options by funds: $86.4M | Put options by funds: $119M

Holders
357
Holders Change
+32
Holders Change %
+9.85%
% of All Funds
9.52%
Holding in Top 10
15
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+25%
% of All Funds
0.4%
New
76
Increased
126
Reduced
120
Closed
36
Calls
$86.4M
Puts
$119M
Net Calls
-$32.4M
Net Calls Change
+$92.4M
Name Holding Trade Value Shares
Change
Change in
Stake
KA
301
Kovack Advisors
Florida
$215K +$218K +1,314 New
BJL
302
Brighton Jones LLC
Washington
$214K -$234K -1,410 -52%
Daiwa Securities Group
303
Daiwa Securities Group
Japan
$213K +$216K +1,300 New
WRM
304
Westport Resources Management
Connecticut
$211K -$24.9K -150 -10%
ICAS
305
Investors Capital Advisory Services
Massachusetts
$210K -$44K -265 -17%
CTC
306
Central Trust Company
Missouri
$209K -$327K -1,970 -61%
EWM
307
Evercore Wealth Management
New York
$192K -$49.8K -300 -20%
QI
308
QS Investors
New York
$148K +$149K +900 New
LIA
309
LS Investment Advisors
Michigan
$138K +$140K +841 New
SAM
310
Solaris Asset Management
New York
$131K
GT
311
Glenmede Trust
Pennsylvania
$115K -$6.97K -42 -6%
HIM
312
Hillsdale Investment Management
Ontario, Canada
$115K
AIM
313
Advantage Investment Management
Iowa
$112K +$113K +681 New
CCS
314
Crosspoint Capital Strategies
California
$108K +$29.4K +177 +37%
Loomis, Sayles & Company
315
Loomis, Sayles & Company
Massachusetts
$93K -$664 -4 -0.7%
Canada Pension Plan Investment Board
316
Canada Pension Plan Investment Board
Ontario, Canada
$82K +$49.8K +300 +150%
NPC
317
National Planning Corporation
California
$81.5K +$83K +500 New
DADC
318
D.A. Davidson & Co
Montana
$71K +$72.2K +435 New
NFG
319
Next Financial Group
Texas
$62K +$48.8K +294 +359%
BKA
320
Brick & Kyle Associates
Pennsylvania
$57K +$58.1K +350 New
OIA
321
Optimum Investment Advisors
Illinois
$57K +$58.1K +350 New
FM
322
Forward Management
California
$49K
BRWM
323
B. Riley Wealth Management
Tennessee
$45K -$4.15K -25 -8%
Bessemer Group
324
Bessemer Group
New Jersey
$40K +$41.3K +249 New
MAM
325
Mizuho Asset Management
Japan
$38K +$39K +235 New

JAZZ Hedge Fund Activity: Q4 2014 in Review

357 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q4 2014, worth a combined $8.94B — up 4.1% from $8.58B a quarter earlier.

Buyers outnumbered sellers: 76 funds opened new JAZZ positions and 36 closed out — a net gain of 40 holders — while 126 added to existing stakes and 120 trimmed.

The largest buyer was American Century Companies, adding an estimated $71.4M. The largest seller was Wells Fargo, cutting an estimated $119M.

  • 357 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q4 2014, up from 325 in Q3 2014.
  • Funds reported $8.94B of Jazz Pharmaceuticals stock for Q4 2014, up 4.1% quarter-over-quarter.
  • 76 funds opened new Jazz Pharmaceuticals positions in Q4 2014 and 36 closed out, a net change of +40 holders.
  • The largest Jazz Pharmaceuticals buyer in Q4 2014 was American Century Companies, an estimated $71.4M added.
  • The largest Jazz Pharmaceuticals seller in Q4 2014 was Wells Fargo, an estimated $119M sold.

Based on aggregated 13F filings for Q4 2014.